Khosraviani K, Weir H P, Hamilton P, Moorehead J, Williamson K
Department of Surgery, Queen's University of Belfast, UK.
Gut. 2002 Aug;51(2):195-9. doi: 10.1136/gut.51.2.195.
Intracellular folate deficiency has been implicated in colonic carcinogenesis in epidemiological studies and animal and human cancer models. Our aim was to determine the effect of folate supplementation on patients with recurrent adenomatous polyps using rectal mucosal cell proliferation as a biomarker.
Eleven patients with recurrent adenomatous polyps of the colon were randomised into a treatment group (n=6) receiving a dietary supplement of 2 mg folic acid per day for three months and a control group (n=5) receiving a placebo. Rectal biopsies where taken at 10 cm from the anal verge prior to supplementation and repeated at four, 12, and 18 weeks from the start of the supplementation. Each biopsy was immediately incubated in culture medium enriched with bromodeoxyuridine (BrdU). The S phase cells which incorporated BrdU into their DNA were identified following immunohistochemical staining. Twenty five orientated crypts were identified for each time point and the number and position of BrdU positive and BrdU negative cells were counted. BrdU labelling indices (LIs) were calculated for the entire crypt and for each of five equal compartments running consequently from the base to the luminal surface.
The LI of the treatment group (9.1 (6.7, 12.3)) and the control group (9.3 (7.8, 10.3)) were comparable at the start. Over the duration of the supplementation period, LI in the control group did not alter significantly (9.3 (7.8, 10.3) v 9.6 (8.9, 10.4)). However, LI of the folate treated group was lowered after 12 weeks of supplementation (9.1 (6.7, 12.3) v 7.4 (5.3, 9.6)). Analysis of the LI for compartments within the crypt showed that the most significant drop in number of proliferating cells was in the upper most regions of the crypt.
These data indicate that (a) folate supplementation decreases colonic mucosal cell proliferation in a high risk group for colon cancer and (b) the most significant reduction takes place at the luminal aspect of the crypt.
在流行病学研究以及动物和人类癌症模型中,细胞内叶酸缺乏已被认为与结肠癌发生有关。我们的目的是通过将直肠黏膜细胞增殖作为生物标志物,来确定补充叶酸对复发性腺瘤性息肉患者的影响。
11例复发性结肠腺瘤性息肉患者被随机分为治疗组(n = 6),每天接受2mg叶酸的膳食补充剂,持续三个月;以及对照组(n = 5),接受安慰剂。在补充前,于距肛门边缘10cm处取直肠活检组织,并在补充开始后的4周、12周和18周重复取材。每次活检组织立即在富含溴脱氧尿苷(BrdU)的培养基中孵育。通过免疫组织化学染色鉴定将BrdU掺入其DNA的S期细胞。每个时间点确定25个定向隐窝,并计数BrdU阳性和BrdU阴性细胞的数量和位置。计算整个隐窝以及从隐窝底部到腔面依次排列的五个相等区域中每个区域的BrdU标记指数(LIs)。
治疗组(9.1(6.7,12.3))和对照组(9.3(7.8,10.3))在开始时的LI相当。在补充期内,对照组的LI没有显著变化(9.3(7.8,10.3)对9.6(8.9,10.4))。然而,叶酸治疗组在补充12周后的LI降低(9.1(6.7,12.3)对7.4(5.3,9.6))。对隐窝内各区域LI的分析表明,增殖细胞数量下降最显著的是隐窝的最上部区域。
这些数据表明,(a)补充叶酸可降低结肠癌高危人群的结肠黏膜细胞增殖,且(b)最显著的减少发生在隐窝的腔面。